慢性阻塞性肺疾病（COPD）是全球第三大致死原因，影响超过2亿人，尤其在中低收入国家造成严重健康负担。其病理机制复杂，表现出显著的异质性，涵盖气道炎症、肺泡破坏和气流受限等多种特征。

本期【刊•见】为诸位介绍一本呼吸系统领域的期刊—COPD: Journal of Chronic Obstructive Pulmonary Disease。除了对关键指标进行详尽解读外，还向您推荐刊内近三年高被引文章，以及近一年高阅读量文章：

• 慢性阻塞性肺病患者体力活动、抑郁和焦虑之间的关系：系统回顾和荟萃分析

• 呼吸练习对健康人和慢性阻塞性肺病患者局部通气的影响

• 2025 GOLD 报告：执业临床医师需要注意哪些新内容和事项

• 慢性阻塞性肺病的生物疗法：随机对照试验的系统性回顾与网状统合分析

Online ISSN: 1541-2563

COPD: Journal of Chronic Obstructive Pulmonary Disease 收稿范围广泛，旨在推动COPD病理生理学、遗传学、诊断、药物与非药物治疗及康复领域的进展。该期刊为讨论、设计和评估更高效的患者护理策略提供了独特平台。

本刊主要读者群体包括：

• 肺病专家

• 内科、全科及家庭医疗医师

• 重症监护专家

• 胸外科医生

• 心脏病学家

• 临床过敏症专家

• 物理治疗师

• 护理人员

• 社会工作者

• 精神科医生及心理学家

该期刊已被SCIE、Scopus、EMBASE、DOAJ、PubMed等十数个国际知名数据库收录。

🌟本刊提供3-5周加速出版服务

影响因子

根据JCR显示，COPD: Journal of Chronic Obstructive Pulmonary Disease

• 在呼吸系统排名 57/108

Scopus

根据Scopus显示, COPD: Journal of Chronic Obstructive Pulmonary Disease

• 2024年CiteScore为 4.8

• 2025年CiteScore Tracker为 3.8

• 在医学：肺和呼吸医学领域排名 56/159

中国科学院文献情报中心期刊分区表

根据2025年3月20日发布的中国科学院文献情报中心期刊分区表显示：

• 大类及分区：医学4区

• 小类及分区：呼吸系统4区

作者须知

接收文章类型

COPD: Journal of Chronic Obstructive Pulmonary Disease 期刊接受原创研究论文、综述论文、专家述评、会议论文集。

审稿周期

• 从提交稿件到获取初审意见，平均需要7天

• 获取首个同行评审决定，平均需要46天

• 稿件一旦接受后，在线出版平均需要23天

文章出版费（APC）

请访问期刊主页或Taylor & Francis Open Access APC Cost Finder查找适用于作者所在国家及不同文章类型的费用情况。若您所在的机构或相关资助者与我们签有开放获取出版协议，您可能有资格获得APC支持，请访问我们的作者服务网站以了解更多！

Taylor & Francis现在开通APC便捷支付功能，可以一键通过微信、支付宝和银联使用人民币便捷付款。

编辑团队

COPD: Journal of Chronic Obstructive Pulmonary Disease 的编辑团队由国际呼吸病学领域的知名专家组成。主编由意大利热那亚大学（University of Genoa）的 Vito Brusasco 教授担任。副主编和编委团队由来自美国、加拿大、意大利、希腊、西班牙、澳大利亚和挪威等多国的权威学者组成。

主编

Vito Brusasco

Vito Brusasco，医学博士，意大利热那亚大学内科与医学专业系呼吸病学教授。他是国际知名的慢性阻塞性肺疾病（COPD）研究专家，长期致力于肺功能检测、气道生理、哮喘机制和肺部疾病的结构-功能关系等领域的研究。

中国编委

郑劲平

郑劲平，教授、博士生导师。广州医科大学南山学院副院长、广州医科大学附属第一医院国家呼吸系统疾病临床医学研究中心副主任。专长于慢性阻塞性肺疾病的研究，研究方向包括呼吸生理与肺功能、慢性气道疾病、呼吸临床药理与临床试验、慢阻肺及呼吸大数据等。

作者分布

根据JCR显示，近三年在COPD: Journal of Chronic Obstructive Pulmonary Disease 上发文较为活跃的国家/地区有：

• 中国

• 加拿大

• 美国

近三年，全球范围内，在COPD: Journal of Chronic Obstructive Pulmonary Disease 上发文数量排名前三的高校和科研机构是：

• 加拿大麦基尔大学

• 加拿大多伦多大学

• 首都医科大学

近三年内高被引文章

The Relationship between Physical Activity, Depression and Anxiety in People with COPD: A Systematic Review and Meta-analyses

慢性阻塞性肺病患者体力活动、抑郁和焦虑之间的关系：系统回顾和荟萃分析

作者：Anne-Marie Selzler et al.

文章摘要：

Depression and anxiety are related to physical activity among people with chronic obstructive pulmonary disease (COPD), although the strength and direction of the reported relationships are inconsistent. This study systematically synthesized the relationships between physical activity and i) depression and ii) anxiety in people with COPD. Physical activity measurement type (objective, self-report) was examined as a moderator of these relationships. A systematic search of physical activity and COPD was conducted from inception to February 2022 across 8 databases. Studies were included if they provided correlation coefficients for the relationship between measures of physical activity and depression or anxiety in people with COPD and were published in English. Two reviewers independently screened, reviewed and extracted data, with discrepancies resolved by a third reviewer. Across 13 studies, a small relationship was found between physical activity and depression, weighted r = −0.15, 95%CI [-0.21, −0.10], which was not moderated by physical activity measurement type. Across 8 studies, a negligible relationship was found between physical activity and anxiety, weighted r = −0.03, 95%CI [-0.11, 0.04], although this was moderated by physical activity measurement type, such that self-reported physical activity had a small negative relationship with anxiety (weighted r = −0.09, 95% CI [-0.15, −0.03]) and objectively measured physical activity had a small positive relationship (weighted r = 0.07, 95% CI [-0.13, 0.26]). In COPD, the bivariate association between physical activity and anxiety and depression are small.

The Influence of Breathing Exercises on Regional Ventilation in Healthy and Patients with Chronic Obstructive Pulmonary Disease

呼吸练习对健康人和慢性阻塞性肺病患者局部通气的影响

作者：Lin Yang et al.

文章摘要：

We hypothesized that the respiratory exercises have uniform effects on ventilation in healthy subjects but the effects varied in patients with chronic obstructive pulmonary disease (COPD). In this study, a total of 30 healthy volunteers and 9 patients with COPD were included. Data were recorded continuously during (1) diaphragmatic breathing; (2) pursed lip breathing with full inhalation; (3) pursed lip combining diaphragmatic breathing. The sequence of the three breathing exercises was randomized using machine generated random permutation. Spatial and temporal ventilation distributions were evaluated with electrical impedance tomography. Results showed that, tidal volume was significantly larger during various breathing exercises compared to quiet tidal breathing, in both healthy and COPD (p < 0.01). However, for other EIT-based parameters, statistical significances were only observed in healthy volunteers, not in patients. Diaphragmatic breathing alone might not be able to decrease functional residual capacity in COPD and the effect varied largely from patient to patient (6:3, decrease vs. increase). Ventilation distribution moved toward ventral regions in healthy during breathing exercises (p < 0.0001). Although this trend was observed in the COPD, the differences were not significant. Ventilation became more homogeneous when diaphragmatic breathing technique was implemented (p < 0.0001). Again, the improvements were not significant in COPD. Regional ventilation delay was relatively high in COPD and comparable in various breathing periods. In conclusions, the impact of pursed lip and diaphragmatic breathing varied in different patients with COPD. Breathing exercise may need to be individualized to maximize the training efficacy with help of EIT.

近一年内高阅读量文章

2025 GOLD Report: What is New and What is Noteworthy for the Practicing Clinician

2025 GOLD 报告：执业临床医师需要注意哪些新内容和事项

作者：Konstantinos Kostikas, Georgios Hillas & Athena Gogali

文章摘要：

The Global initiative for chronic Obstructive Lung Disease (GOLD) report is revised annually and released each November in parallel with World COPD Day. The 2025 GOLD report has incorporated multiple changes with clinical relevance, including the diagnostic approach with spirometry and other tests, the management of patients with cardiovascular comorbidities and pulmonary hypertension, novel treatments and the refinement of the use of older ones, and the proactive management to minimize future risk of COPD patients.

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

慢性阻塞性肺病的生物疗法：随机对照试验的系统性回顾与网状统合分析

作者：Tyler Pitre et al.

文章摘要：

Background

Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.

Methods

We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD. We performed a random effects frequentist network meta-analysis and present the results using relative risk (RR) and 95% confidence intervals (CI). We used the GRADE framework to rate the certainty of the evidence. Outcomes of interest included exacerbations, change in FEV1, change in quality of life, and serious adverse events.

Results

Dupilumab reduced exacerbations as compared to placebo (RR 0.68 [95% CI 0.59 to 0.79]) (high certainty). Benralizumab (RR 0.89 [95% CI 0.78 to 1]), itepekimab (RR 0.81 [95% CI 0.61 to 1.07]) and tezepelumab (RR 0.83 [95% CI 0.61 to 1.12]) may reduce exacerbations as compared to placebo (all low certainty). Dupilumab probably reduced exacerbations more than mepolizumab (RR 0.74 [95% CI 0.62 to 0.89]) (moderate certainty). Dupilumab may reduce exacerbations more than tezepelumab (RR 0.82 [95% CI 1.14]) (low certainty). For all patients, no treatment improved FEV1 above the pre-specified minimal clinically important difference (MCID) of 0.1 L. Dupilumab probably has no meaningful effect on FEV1 compared to placebo (MD 0.07 [95% CI 0.02 to 0.13]) (moderate certainty). However, in the subgroup of patients with blood eosinophils ≥300/mcL, both tezepelumab (MD 0.15 [95% CI 0.05 to 0.26]) and dupilumab (MD 0.13 [95% CI 0.06 to 0.19]) probably improved FEV1 above the MCID.

Conclusion

Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.

Figure 1. PRISMA diagram presenting the inclusion and exclus

"Jour - Know"

为帮助更多科研人员选择更加合适的期刊，Taylor & Francis推出专栏——刊·见，该专栏致力于为读者和广大科研人员带来Taylor & Francis旗下期刊的详细解读，从期刊的基本情况、编委阵容、社会影响力到审稿速度、高被引文章等实用信息，专栏将为您带来最详细的介绍，让您更加全面地了解Taylor & Francis旗下优秀的国际期刊，帮助更多中国卓越科研成果顺利在国际期刊上发表。